FDA approves Korlym for hyperglycemia in patients with endogenous Cushing’s syndrome

On Feb. 17, the U.S. Food and Drug Administration (FDA) announced the approval of Korlym (mifepristone) to control hyperglycemia in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here